What muscle relaxant and dosing regimen is appropriate for a post‑stroke patient experiencing painful muscle spasticity?

Muscle Relaxant Selection for Post-Stroke Spasticity

For post-stroke painful muscle spasticity, botulinum toxin injections are the first-line treatment for focal spasticity, while oral baclofen (30-80 mg/day in divided doses) or tizanidine are appropriate for generalized spasticity, with botulinum toxin showing comparable efficacy to oral agents but with superior tolerability. 1

Treatment Algorithm Based on Spasticity Distribution

Focal Spasticity (Specific Muscle Groups)

• Botulinum toxin injections are recommended as first-line therapy for localized upper or lower limb spasticity to reduce tone, improve range of motion, and facilitate hygiene and positioning 1
• Dosing: 100-300 IU based on predetermined anatomical diagrams, targeting specific affected muscle groups 1
• For ankle spasticity specifically, botulinum toxin demonstrates superior efficacy over oral agents (1-point improvement on Modified Ashworth Scale) 1

Generalized Spasticity (Multiple Limb Involvement)

Oral antispasticity agents are appropriate but carry dose-limiting sedation risk 1:

• Baclofen: 30-80 mg/day in multiple divided doses, titrated to effect and tolerance 1

  • Fair evidence supports efficacy compared to placebo in stroke patients 2
  • Roughly equivalent efficacy to tizanidine but causes more weakness 2

• Tizanidine: Alternative first-line oral agent 1, 2

  • Fair evidence for efficacy in spasticity 2
  • More dry mouth than baclofen but less weakness 2
  • Comparable overall adverse event rate to baclofen 2

• Tolperisone: 300-900 mg/day (individualized titration, may exceed standard 450 mg maximum) 3, 4

  • Reduced Ashworth Score by mean 1.03 points versus 0.47 for placebo 3
  • Superior efficacy and tolerability profile compared to other oral agents in comparative studies 4
  • Fewer adverse events than placebo in controlled trials 3

Key Clinical Considerations

Timing and Contraindications

• Oral agents can be initiated early in the post-stroke period for generalized spasticity 1
• Intrathecal baclofen may be considered at 3-6 months post-stroke for severe spasticity refractory to oral medications and botulinum toxin 1

Important Caveats

• Spasticity can be functionally beneficial: Many hemiplegic patients rely on extensor muscle spasticity to brace the lower limb for ambulation despite weakness 5
• Before initiating pharmacotherapy, always evaluate and treat aggravating factors: urinary tract infections, constipation/fecal impaction, pressure ulcers, and bladder stones, as treating these may reduce tone without medication 5
• The 2024 VA/DoD guideline downgraded botulinum toxin from "strong for" to "weak for" based on a small trial showing no dramatic efficacy difference from oral baclofen except in ankle spasticity 1

Agents to Avoid

• Dantrolene: Associated with rare but serious hepatotoxicity 2, 6
• Splints and taping: Not recommended for prevention of wrist/finger spasticity 1

Adjunctive Therapies

Physical modalities may provide temporary benefit as adjuncts 1:

• Neuromuscular electrical stimulation (NMES)
• Vibration therapy
• These should supplement, not replace, pharmacological management